Cessatech A/S (FRA:8GN)

Market Cap	34.81M
Revenue (ttm)	-615.78K
Net Income (ttm)	-2.32M
Shares Out	n/a
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	550
Average Volume	28
Open	1.644
Previous Close	1.634
Day's Range	1.644 - 2.060
52-Week Range	0.775 - 2.085
Beta	n/a
RSI	72.76
Earnings Date	Feb 27, 2026

About Cessatech

Cessatech A/S, a pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for sedative procedures for children from 0-17 years of age; and CT003, a local anesthetic gel. The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies. Cessatech A/S...

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8GN

Financial Performance

Financial numbers in DKK